Ranexa May Launch In 2006; CV Therapeutics And FDA Discussing New Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to obtain a special protocol assessment for the trial, which will likely focus on a restricted angina population. After approval, CVT expects to expand the label through additional studies.